REG - Hutchmed China Ltd - Vesting of awards under the LTIP

HUTCHMED (China)Announcement

05/03/2024 08:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240305:nRSE5258Fa&default-theme=true

RNS Number : 5258F  Hutchmed (China) Limited  05 March 2024

Vesting of awards under the Long Term Incentive Plan

 

Hong Kong, Shanghai & Florham Park, NJ - Tuesday, March 5, 2024: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) ") (Nasdaq/AIM: HCM;
SEHK:13) announces that following the announcement of the 2023 annual results
of HUTCHMED on February 28, 2024, the following awards granted under the Long
Term Incentive Plan ("LTIP") on March 26, 2021 to Dr Weiguo Su and Mr Johnny
Cheng were vested on March 4, 2024:-

 

 Award Holders                                                                   Number of American depositary shares ("ADS")
 Person Discharging Managerial Responsibilities
 Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific  93,545
 Officer)
 Mr Johnny Cheng (Executive Director and Chief Financial Officer)                15,141
 Total                                                                           108,686

 

The notifications set out below are provided in accordance with the
requirements of the EU Market Abuse Regulation.

 

(a)  Dr Weiguo Su

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 a)   Name                                                          Dr Weiguo Su

 2    Reason for the notification

 a)   Position/status                                               Executive Director, Chief Executive Officer and Chief Scientific Officer

 b)   Initial notification/Amendment                                Initial notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor

 a)   Name                                                          HUTCHMED (China) Limited

 b)   LEI                                                           2138006X34YDQ6OBYE79

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument   ADS each representing five Ordinary Shares of US$0.10

      Identification code

                                                                    ADS ISIN: US44842L1035

 b)   Nature of the transaction                                     Vesting of awards granted on March 26, 2021 under HUTCHMED's LTIP

Price(s)  Volume(s)
 c)   Price(s) and volume(s)                                        Nil       93,545 ADS

 d)   Aggregated information                                        N/A

      - Aggregated volume
      - Price

 e)   Date of the transaction                                       2024-03-04

 f)   Place of the transaction                                      Outside a trading venue

 

d)

 

Aggregated information

 -  Aggregated volume
 -  Price

 

N/A

 

e)

 

Date of the transaction

 

2024-03-04

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 

(b)  Mr Johnny Cheng

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 a)   Name                                                          Mr Johnny Cheng

 2    Reason for the notification

 a)   Position/status                                               Executive Director and Chief Financial Officer

 b)   Initial notification/Amendment                                Initial notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor

 a)   Name                                                          HUTCHMED (China) Limited

 b)   LEI                                                           2138006X34YDQ6OBYE79

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument   ADS each representing five Ordinary Shares of US$0.10

      Identification code

                                                                    ADS ISIN: US44842L1035

 b)   Nature of the transaction                                     Vesting of awards granted on March 26, 2021 under HUTCHMED's LTIP

Price(s)  Volume(s)
 c)   Price(s) and volume(s)                                        Nil       15,141 ADS

 d)   Aggregated information                                        N/A

      - Aggregated volume
      - Price

 e)   Date of the transaction                                       2024-03-04

 f)   Place of the transaction                                      Outside a trading venue

 

d)

 

Aggregated information

 -  Aggregated volume
 -  Price

 

N/A

 

e)

 

Date of the transaction

 

2024-03-04

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception it has focused on bringing
cancer drug candidates from in-house discovery to patients around the world,
with its first three medicines marketed in China, the first of which is also
marketed in the U.S. For more information, please visit: www.hutch-med.com
(http://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

CONTACTS

 

 Investor Enquiries                                +852 2121 8200 / +1 973 306 4490 / ir@hutch-med.com
                                                   (mailto:ir@hutch-med.com)

 Media Enquiries
 Ben Atwell / Alex Shaw, FTI Consulting            +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
                                                   +44 7779 545 055 (Mobile)   HUTCHMED@fticonsulting.com
                                                   (mailto:HUTCHMED@fticonsulting.com)
 Zhou Yi, Brunswick                                +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                   (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Daphne Zhang,  +44 (20) 7886 2500

Panmure Gordon

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHJIMFTMTJMBAI